LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 1 | D03 | 72 | hr | 2543 | 4819 | 5734 | 0.8404 | 0.7244 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 2 | D03 | 72 | hr | 2543 | 5136 | 5761 | 0.8915 | 0.8144 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 3 | D03 | 72 | hr | 2543 | 5080 | 5760 | 0.8818 | 0.7977 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 1 | I02 | 72 | hr | 2543 | 2947 | 5258 | 0.5604 | 0.1509 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 2 | I02 | 72 | hr | 2543 | 3334 | 5438 | 0.6131 | 0.2800 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 3 | I02 | 72 | hr | 2543 | 3490 | 5557 | 0.6280 | 0.3239 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 1 | D02 | 72 | hr | 2543 | 4250 | 5734 | 0.7411 | 0.5492 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 2 | D02 | 72 | hr | 2543 | 4047 | 5761 | 0.7024 | 0.4825 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 3 | D02 | 72 | hr | 2543 | 4346 | 5760 | 0.7544 | 0.5749 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP6 | 1 | I01 | 72 | hr | 2543 | 1065 | 5258 | 0.2025 | -0.5643 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP6 | 2 | I01 | 72 | hr | 2543 | 1533 | 5438 | 0.2819 | -0.3699 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP6 | 3 | I01 | 72 | hr | 2543 | 1462 | 5557 | 0.2631 | -0.3880 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP5 | 1 | D01 | 72 | hr | 2543 | 2600 | 5734 | 0.4534 | 0.0189 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP5 | 2 | D01 | 72 | hr | 2543 | 2577 | 5761 | 0.4473 | 0.0112 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP5 | 3 | D01 | 72 | hr | 2543 | 2443 | 5760 | 0.4241 | -0.0336 |
| SK-BR-3 | Tozasertib | 0.04 | uM | LJP5 | 1 | B18 | 72 | hr | 2543 | 1573 | 5734 | 0.2743 | -0.3362 |
| SK-BR-3 | Tozasertib | 0.04 | uM | LJP5 | 2 | B18 | 72 | hr | 2543 | 1934 | 5761 | 0.3357 | -0.2072 |
| SK-BR-3 | Tozasertib | 0.04 | uM | LJP5 | 3 | B18 | 72 | hr | 2543 | 1882 | 5760 | 0.3267 | -0.2254 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 1 | B17 | 72 | hr | 2543 | 1910 | 5734 | 0.3331 | -0.2167 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 2 | B17 | 72 | hr | 2543 | 1997 | 5761 | 0.3466 | -0.1854 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 3 | B17 | 72 | hr | 2543 | 2010 | 5760 | 0.3489 | -0.1809 |
| SK-BR-3 | Tozasertib | 0.37 | uM | LJP5 | 1 | B16 | 72 | hr | 2543 | 1918 | 5734 | 0.3345 | -0.2139 |
| SK-BR-3 | Tozasertib | 0.37 | uM | LJP5 | 2 | B16 | 72 | hr | 2543 | 2026 | 5761 | 0.3517 | -0.1754 |
| SK-BR-3 | Tozasertib | 0.37 | uM | LJP5 | 3 | B16 | 72 | hr | 2543 | 2019 | 5760 | 0.3505 | -0.1778 |
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 1 | B15 | 72 | hr | 2543 | 1912 | 5734 | 0.3334 | -0.2160 |